AbbVie Receives FDA Approval for VYALEV™: First Continuous Subcutaneous Infusion Therapy for Advanced Parkinson's Disease

AbbVie (NYSE: ABBV) announced that the U.S. Food and Drug Administration (FDA) has approved VYALEV™ (foscarbidopa and foslevodopa) as the first and o...

October 18, 2024 | Friday | News
MSD's Clesrovimab Shows Promising Results in Protecting Infants from RSV in Phase 2b/3 Trial

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced the presentation of positive results from the Phase 2b/3 clinical trial ...

October 18, 2024 | Friday | News
Alnylam Pharmaceuticals Submits Type II Variation for Vutrisiran to Treat ATTR Amyloidosis with Cardiomyopathy

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, announced the submission of a Type II Variatio...

October 17, 2024 | Thursday | News
Eisai and Biogen Seek Reconsideration of Lecanemab Registration Decision in Australia

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusett...

October 17, 2024 | Thursday | News
Merck Presents Promising Phase 3 Results for CAPVAXIVE™ Vaccine at IDWeek 2024

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced results from STRIDE-8, a Phase 3 trial evaluating CAPVAXIVE™ (Pneu...

October 17, 2024 | Thursday | News
AstraZeneca Unveils Groundbreaking Data on Vaccines and Immune Therapies at IDWeek 2024

AstraZeneca will share new data across its Vaccines & Immune Therapies portfolio at the 13th annual IDWeek in Los Angeles, California, from 16-19 ...

October 17, 2024 | Thursday | News
InSphero and FDA Publish Landmark Study on Liver Toxicology Using 3D InSight™ Microtissues

 InSphero, the global leader in 3D cell culture technology, and scientists from the U.S. Food and Drug Administration's (FDA) National Cente...

October 16, 2024 | Wednesday | News
AtomVie and Radiopharm Ventures Partner to Develop Targeted Radiopharmaceutical 177Lu-BetaBart

AtomVie Global Radiopharma (AtomVie), a leading radiopharmaceutical Contract Development and Manufacturing Organization (CDMO), has entered into an agreeme...

October 16, 2024 | Wednesday | News
Jazz Pharmaceuticals Reports Positive Phase 3 Results for Zepzelca® Combined with Atezolizumab in Small Cell Lung Cancer

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced positive top-line results from the Phase 3 clinical trial evaluating Zepzelca® (lurbinected...

October 16, 2024 | Wednesday | News
Amgen Announces Positive Phase 3 Results for UPLIZNA® in Generalized Myasthenia Gravis, Paving the Way for New Treatment Options

Amgen (NASDAQ:AMGN) announced the presentation of positive top-line results from the Phase 3 MINT trial evaluating the efficacy and safety of UPLIZNA&...

October 16, 2024 | Wednesday | News
Biofrontera Completes Treatment Phase in First U.S. Phase 3 PDT Study for sBCC, Data Analysis Underway

First Phase 3 PDT study in patients with sBCC in the United States. Rigorous dual endpoints requiring complete clinical and cytological clearance of m...

October 15, 2024 | Tuesday | News
Eli Lilly's Mirikizumab Shows Promising Histologic Response in Phase 3 Study for Crohn's Disease, Outperforming Ustekinumab

Eli Lilly and Company (NYSE: LLY) announced data demonstrating more patients with moderately to severely active Crohn's disease treated with miri...

October 15, 2024 | Tuesday | News
Exelixis and MSD Announce Strategic Collaboration to Evaluate Zanzalintinib in Combination with KEYTRUDA® and WELIREG® for Advanced Cancers

Exelixis, Inc. (Nasdaq: EXEL) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that the companies have entered i...

October 15, 2024 | Tuesday | News
BD and Hamilton Robotics Launch Automation-Ready Reagents to Transform Genomic Sequencing Workflows

  Automation-Ready Reagents Used with the Hamilton Robotics Liquid-Handler Streamlines and Helps Accelerate Lab Work Leading to Genomic Sequencing&nb...

October 15, 2024 | Tuesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2024 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close